I
n conjunction with 2 pairs of nonidentical light chains, 2 myosin heavy chain (MyHCs) constitute the functional myosin motor molecule. Two isoforms of MyHC (␣ and ␤) are expressed in mammalian heart. Myosin consisting of ␣MyHC has a higher ATPase activity than myosin composed of ␤MyHC, 1 and in the rodent heart, contractile velocity correlates with the relative amount of each MyHC. Hearts expressing ␣MyHC have more rapid contractile velocity than hearts expressing ␤MyHC, which allows greater economy in force generation because the tension-time integral for force per cross-bridge cycle is greater. 2, 3 The MyHC composition of the ventricular myocardium of rodents has been reported to be Ͼ90% ␣MyHC, 4 -6 whereas that of humans has been reported to be Ͼ95% ␤MyHC. [7] [8] [9] [10] [11] [12] [13] In the rodent heart, thyroid hormone elevation and exercise have been shown to increase ␣MyHC, whereas thyroid depletion, aging, cardiomyopathy, and pressure overload have been shown to increase ␤MyHC (see Swynghedauw 14 ) . Because the normal human heart was previously thought to be entirely ␤MyHC, [7] [8] [9] [10] [11] [12] [13] stimuli that might induce isoform shifts toward ␤MyHC in human heart disease were thought to be irrelevant.
The MyHC composition of human heart was originally investigated with immunohistochemistry, because of the difficulty in electrophoretic separation of the human ␣MyHC and ␤MyHC, 9 or by peptide mapping. 7, 10 Immunohistochemistry can show the spatial expression of each isoform, but it is not quantitative because 2 different antibodies cannot be directly compared. 15, 16 The results of immunohistochemical analysis were quite varied, with reports ranging from Ͻ5% to 88% of myocytes expressing ␣MyHC. 8, 11, 12 We showed that ␣MyHC mRNA was expressed at considerable levels in the nonfailing human left ventricles (LVs) and was substantially decreased in end-stage failing human LVs. 17, 18 The proportion of total MyHC mRNA that is ␣MyHC mRNA was Ϸ30% in nonfailing LVs and was reduced by 15-fold, to Ϸ2%, in end-stage LVs.
Because of the potential functional significance of altered MyHC composition in contractility and to gain insight into the molecular mechanisms of changes in gene expression in heart failure, we quantified ␣MyHC and ␤MyHC proteins in human nonfailing and failing LVs according to a recently reported gel electrophoretic method. 19 We demonstrate that ␣MyHC protein is detectable in nonfailing LVs but is virtually undetectable in failing LVs.
Materials and Methods
Patients from whom hearts were provided through the Colorado Transplant Program are described in Tables 1 and 2 . 17 LVs were obtained from 12 control organ donor candidates (5 men and 7 women, mean age 36.8Ϯ16.9 years) and 10 patients undergoing heart transplantation (8 men and 2 women, mean age 44.9Ϯ19.3 years).
RNA was extracted and analyzed with quantitative polymerase chain reaction as previously described and reported. 17, 18 Samples for protein gel electrophoresis (15 to 200 mg) were prepared as described by Caforio et al 20 from tissue that had no visible fat and no connective tissue. Briefly, samples were homogenized in low-salt buffer (20 mmol/L KCl, 2 mmol/L KH 2 PO 4 , 1 mmol/L EGTA, pH 6.8, 1 mmol/L PMSF, 100 L N,N-dimethyl formamide). The samples were then centrifuged at 5000 rpm for 10 minutes at 4°C in a JA-17 rotor (Beckman Instruments). Pellets were suspended in high-salt buffer (40 mmol/L Na 4 P 2 O 7 , 1 mmol/L MgCl 2 , 1 mmol/L EGTA, pH 9.5) and then centrifuged at 15 000 rpm for 30 minutes at 4°C. Laemmli's buffer was added to each sample, and then each sample was boiled. 21 The preparation and composition of the gel were carried out as described by Reiser and Kline. 19 Gel samples (0.25 to 1 g) were loaded in a 3-L volume onto 15-well gels. The stacking and separating gels (0.75 mm thick) consisted of 4% and 8% acrylamide, respectively; the stacking gels included 5% glycerol. The gels were run in a Hoeffer Scientific SE600 instrument at 5°C. The gels were run at a constant voltage of 200 V for 30 hours. The gels were fixed and silver stained as described in Blough et al. 22 A gel documentation system (BioRad) was used to scan the stained gels. The abundance of ␣MyHC and ␤MyHC was determined with quantitative reverse transcription-polymerase chain reaction as previously described. 17, 18 Protein samples were subjected to electrophoresis as described earlier and transferred to 0.2-m nitrocellulose. The blots were blocked in 10% nonfat dry milk in PBS for 2 hours at room temperature. Blots were incubated with a monoclonal antibody against sarcomeric MyHC (F59) 23 or F88.12F8 (Alexis Biochemicals) at a dilution of 1:500 or 1:5000, respectively, in 5% BSA overnight at 4°C. After primary antibody incubations, 3 washes in PBS were followed by an incubation in the secondary antibody, peroxidaseconjugated goat anti-mouse IgG (Jackson Laboratories) diluted 1:5000 in 10% nonfat dry milk in PBS for 2 hours at room temperature. The blots were then washed 3 times in 0.05% NP-40/PBS. Immunoreactive bands were visualized by using the Renaissance Western Blot Chemiluminescence Reagent (NEN Life Sciences). DOA/DOB indicates dopamine/dobutamine at organ harvest; MVA, motor vehicle accident; CVA, cerebrovascular accident; SIGSW, self-inflicted gunshot wound; CAD, coronary artery disease; AV, aortic valve; MV, mitral valve; and DHD, donor heart dysfunction, with generalized hypokinesis and estimated LV ejection fraction of 0.20 to 0.25.
*RNA levels were determined with the method described previously. 18 The remainder were carried out as described previously. 17 
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Results and Discussion
The goals of the present study were to determine the amount of ␣MyHC protein in the nonfailing and failing human hearts and to determine the relationship between MyHC mRNA and protein levels. The clinical characteristics and the ␣MyHC mRNA content of the patients analyzed in the present study are shown in Tables 1 and 2 . The range of ␣MyHC mRNA was 10.8% to 55% in nonfailing LVs and 0% to 8.8% in failing LVs. To identify ␣MyHC protein, immunoblot analysis was carried out with a monoclonal antibody specific to ␣MyHC protein. 15 To quantify the proportion of ␣MyHC protein, an electrophoretic separation protocol was used, followed by silver staining and densitometry. Figure 1 is an immunoblot performed on a high-resolution gel that separates ␣MyHC and ␤MyHC proteins. The gel was probed with pansarcomeric MyHC antibody F59 23 (top) and an ␣MyHC-specific antibody (bottom). 15 Lane 1 represents rabbit skeletal MyHC, used as a control. It was recognized by the pansarcomeric MyHC antibody but not by the ␣MyHC-specific antibody. ␣MyHC was prominently expressed in a right atrial sample (lane 2), as expected. 24 As an additional control, the right atrial sample was mixed 1:1 with an LV sample (lane 3). Two bands were recognized by the pansarcomeric antibody, but only the top band was recognized by the ␣MyHC antibody. ␣MyHC was easily detectable in 2 nonfailing LVs (lanes 4 and 5). These results demonstrate that human ␣MyHC and ␤MyHC can be resolved into 2 bands and that the slower migrating species is ␣MyHC. However, this immunoblot analysis does not provide quantitative information about ␣MyHC levels. For that purpose, a high-resolution gel was run, silver stained, and subjected to laser scanning densitometry. Figure 2 is a representative silver-stained gel of MyHC from nonfailing and failing LVs. The results of the scan are presented in Tables 1 and 2 . The RA (right atrial) sample contained 86% ␣MyHC and 14% ␤MyHC and served as a positive control 24 ( Figure 2 ). ␣MyHC protein was detected in all 12
nonfailing LVs and corresponded to 7.2Ϯ3.2% of total MyHC ([meanϮSD] range 1.2% to 13%). One patient's heart that was originally included in the nonfailing group had no ␣MyHC protein. However, when the clinical characteristics were examined in greater detail, it was found that this patient had a history of myocardial infarction and exhibited an anterior wall motion abnormality; data on this patient's tissue were subsequently eliminated from the analysis. However, the finding of no ␣MyHC protein in a setting of LV dysfunction suggests that changes in cardiac MyHC expression can precede the development of overt myocardial failure. ␣MyHC protein was barely detectable (0.75%) in 1 of 10 failing LVs, from an 18-year-old patient with idiopathic dilated cardiomyopathy and with 8.8% ␣MyHC mRNA (Figure 2 ). No ␣MyHC protein was detected in the remaining 9 failing LV samples. Investigation into the molecular and cellular mechanisms of heart failure has provided some insight into changes in gene expression that could contribute to contractile dysfunction. Given the potential functional significance of ␣MyHC protein in the myocardium, it was important to determine whether protein was also present. ␣MyHC protein was detected all 12 nonfailing LVs but was undetectable in 9 of 10 failing LVs and barely detectable in the remaining failing LV. Interestingly, in all nonfailing LVs, there was more ␣MyHC mRNA than protein (see Table 1 ). Discordance between MyHC mRNA and protein has been demonstrated in several reports and systems. 25 For example, electrical stimulation of adult cardiac myocyte contraction accelerates MyHC synthesis by increasing the rate of translation initiation. This occurs in the absence of an increase in mRNA abundance. 26 After 7 days of ascending aortic constriction, ␤MyHC protein increases from 5% to 31% of total MyHC in the absence of changes in mRNA abundance. 27 Finally, contractile arrest of cardiac myocytes has been shown to inhibit MyHC synthesis and to decelerate MyHC degradation. 28 Protein synthesis in the heart is regulated by changes in efficiency and capacity and has been shown to vary widely depending on the stimulus. 29 -31 Before drawing firm conclusions about the degree of discordance between mRNA and protein, 1 limitation of the silver-staining approach should be noted: in samples with very low amounts of ␣MyHC, the ␤MyHC band may obscure a faint ␣MyHC band. To complement the approach used here and to be able to determine the absolute quantities of ␣ and ␤MyHC, we are in the process of developing ELISAs.
One question that arises from these observations is whether a relatively small amount of ␣MyHC is capable of Figure 1 . Immunodetection of ␣MyHC and ␤MyHC after highresolution gel electrophoresis. Top, Probed with F59, which recognizes all sarcomeric MyHCs. 23 Bottom, Probed with F88.12.F8, which is specific to ␣MyHC. 15 Figure 2 . Separation of human ␣MyHC and ␤MyHC proteins. Protein samples of human left ventricles were resolved on an SDS-8% polyacrylamide gel. The gel was fixed and silver stained as described previously. 19 The relative amounts of ␣MyHC and ␤MyHC protein in nonfailing and failing heart LVs were determined with scanning densitometry and are presented in Tables 1 and 2. changing the contractile properties of the heart. Thus far, the cases in which shifts in myosin composition have been studied have generally been at end points where the shift has been quite large. The impact of small shifts such as those described here have not yet been reported. However, with the assumption of a 3-fold difference in the velocity of shortening in muscles expressing the ␣ and ␤ isoforms, the decrease in ␣MyHC from 7.5% to Ͻ0.1% could theoretically reduce systolic function by 12.5%, although the direct relationship to velocity of contraction would have to be tested directly. In support of this hypothesis, we recently used transgenesis to express ␤MyHC in the adult mouse heart, which normally expresses exclusively ␣MyHC. When only 12% of the total MyHC is ␤MyHC, there is a significant decrease in systolic function and Ca ϩ2 -activated myofibrillar ATPase activity. 32 However, in vitro biochemical mixing experiments with varying proportions of ␣ and ␤ myosin show that ␤ myosin can have a "slowing" effect on ␣ myosin, suggesting that the impact of myosin changes in the intact heart may not reflect the behavior of purified molecules in solution. 33 The sensitivity of the cardiac sarcomere to alterations in MyHC has been emphasized by the discovery of Ͼ50 alleles of the ␤MyHC gene found in patients with hypertrophic cardiomyopathy (see Bonne et al 34 ). Most of these alleles have mutations in the motor domain, and in vitro biochemical studies have shown that the motor activity is impaired in at least 3 different alleles. [35] [36] [37] Somewhat surprisingly, the functional differences in the mutant alleles are less than the difference between wild-type ␣MyHC and ␤MyHC. 37 Further investigation is required to understand the relationship of decreased myosin motor activity and the pathogenesis of hypertrophic cardiomyopathy and heart failure.
In summary, we separated human ␣MyHC and ␤MyHC proteins through electrophoresis and quantified the relative amounts of ␣MyHC and ␤MyHC in nonfailing and failing LVs. ␣MyHC is detectable in nonfailing LVs but effectively undetectable in failing LVs. Future experiments will be directed toward a determination of the mechanism of ␣MyHC mRNA decrease and the relevance of changes in MyHC gene expression to human cardiac function.
